JP2011525477A5 - - Google Patents

Download PDF

Info

Publication number
JP2011525477A5
JP2011525477A5 JP2010549861A JP2010549861A JP2011525477A5 JP 2011525477 A5 JP2011525477 A5 JP 2011525477A5 JP 2010549861 A JP2010549861 A JP 2010549861A JP 2010549861 A JP2010549861 A JP 2010549861A JP 2011525477 A5 JP2011525477 A5 JP 2011525477A5
Authority
JP
Japan
Prior art keywords
vaccine composition
particles
aspect ratio
antigen
immunostimulatory agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010549861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011525477A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/036068 external-priority patent/WO2009111588A1/en
Publication of JP2011525477A publication Critical patent/JP2011525477A/ja
Publication of JP2011525477A5 publication Critical patent/JP2011525477A5/ja
Pending legal-status Critical Current

Links

JP2010549861A 2008-03-04 2009-03-04 免疫調節剤粒子および処置方法 Pending JP2011525477A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6822708P 2008-03-04 2008-03-04
US61/068,227 2008-03-04
PCT/US2009/036068 WO2009111588A1 (en) 2008-03-04 2009-03-04 Immunomodulator particles and methods of treating

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014238952A Division JP2015078204A (ja) 2008-03-04 2014-11-26 免疫調節剤粒子および処置方法

Publications (2)

Publication Number Publication Date
JP2011525477A JP2011525477A (ja) 2011-09-22
JP2011525477A5 true JP2011525477A5 (enExample) 2012-04-26

Family

ID=41056361

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010549861A Pending JP2011525477A (ja) 2008-03-04 2009-03-04 免疫調節剤粒子および処置方法
JP2014238952A Pending JP2015078204A (ja) 2008-03-04 2014-11-26 免疫調節剤粒子および処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014238952A Pending JP2015078204A (ja) 2008-03-04 2014-11-26 免疫調節剤粒子および処置方法

Country Status (5)

Country Link
US (2) US20110151015A1 (enExample)
EP (1) EP2262480B1 (enExample)
JP (2) JP2011525477A (enExample)
CN (1) CN102014874A (enExample)
WO (1) WO2009111588A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100055459A1 (en) * 2006-08-30 2010-03-04 Liquidia Technologies, Inc. Nanoparticles Having Functional Additives for Self and Directed Assembly and Methods of Fabricating Same
US20100190654A1 (en) * 2006-12-05 2010-07-29 Liquidia Technologies , Inc. Nanoarrays and methods and materials for fabricating same
DK2131856T3 (da) 2007-03-07 2014-12-15 Uti Limited Partnership Sammensætninger og fremgangsmåder til forebyggelsen og behandlingen af autoimmune tilstande
WO2010138193A2 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
CN102834112B (zh) * 2010-02-22 2016-02-24 流体科技公司 多糖颗粒疫苗
US20110293700A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
WO2012037358A1 (en) 2010-09-16 2012-03-22 The University Of North Carolina At Chapel Hill Asymmetric bifunctional silyl monomers and particles thereof as prodrugs and delivery vehicles for pharmaceutical, chemical and biological agents
EP2640190A4 (en) 2010-11-05 2016-05-11 Selecta Biosciences Inc MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
CN103501812A (zh) 2011-04-29 2014-01-08 西莱克塔生物科技公司 用于过敏症治疗的致耐受性合成纳米载体
CN109172819A (zh) 2011-07-29 2019-01-11 西莱克塔生物科技公司 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
WO2013082111A2 (en) 2011-11-29 2013-06-06 The University Of North Carolina At Chapel Hill Geometrically engineered particles and methods for modulating macrophage or immune responses
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
WO2014165728A1 (en) * 2013-04-05 2014-10-09 The University Of North Carolina At Chapel Hill Particles having peg-ylated surfaces modified for lymphatic trafficking
SG10201912301XA (en) 2013-11-04 2020-02-27 Uti Lp Methods and compositions for sustained immunotherapy
US12011480B2 (en) 2015-05-06 2024-06-18 Uti Limited Partnership Nanoparticle compositions for sustained therapy
BE1024210B1 (fr) 2016-03-07 2017-12-18 Glaxosmithkline Biologicals Sa Particules pour l'administration de medicaments
IL262720B2 (en) 2016-05-05 2024-06-01 Liquidia Tech Inc Dry powder treprostinil for the treatment of pulmonary hypertension
CN111741746A (zh) 2017-11-29 2020-10-02 乌第有限合伙公司 治疗自身免疫性疾病的方法
US20230241237A1 (en) * 2020-04-16 2023-08-03 Emory University Immune Cell Redirecting Compositions and Therapeutic Uses Thereof
CN116407624B (zh) * 2023-04-14 2024-04-09 吉林省农业科学院(中国农业科技东北创新中心) 一种鸡传染性支气管炎细菌样颗粒疫苗的制备方法和应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5709879A (en) 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
GB9227068D0 (en) * 1992-12-29 1993-02-24 British Bio Technology Novel proteinaceous particles
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
US5686113A (en) 1995-03-21 1997-11-11 Temple University Of The Commonwealth System Of Higher Education Microcapsules of predetermined peptide(s) specificity (ies), their preparation and uses
WO1999030737A1 (en) * 1997-12-16 1999-06-24 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
US6086881A (en) * 1998-05-15 2000-07-11 Children's Medical Center Corp. Spatially aligned conjugated composition having a thioether bond linkage
EP1129209B1 (en) * 1998-11-11 2009-01-21 The Board Of Regents Of The University Of Oklahoma Polymer grafting by polysaccharide synthases
US6326021B1 (en) * 1999-06-18 2001-12-04 The Ohio State University Research Foundation Biocompatible polymeric delivery systems having functional groups attached to the surface thereof
WO2001008636A2 (en) * 1999-08-03 2001-02-08 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
US20020061312A1 (en) * 2000-07-31 2002-05-23 Ruslan Medzhitov Innate immune system-directed vaccines
US20030232055A1 (en) 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
US20030175287A1 (en) 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
CA2446458A1 (en) * 2001-05-09 2002-11-14 Yale University Toll/interleukin-1 receptor adaptor protein (tirap)
CA2473281A1 (en) * 2002-01-09 2003-07-24 Richard A. Flavell Irak-m is a negative regulator of toll-like receptor signaling
AU2003235685A1 (en) * 2002-01-09 2003-07-30 Ruslan M. Medzhitov Rip2: a method of signaling in the innate and adaptive immune systems
WO2003087757A2 (en) * 2002-04-05 2003-10-23 Progenics Pharmaceuticals, Inc. Particle-bound human immunodeficiency virus envelope clycoproteins and related compositions and methods
AU2003225054A1 (en) * 2002-04-19 2003-11-03 Yale University Toll-like receptor 11 and toll-like receptor 12
US20040009943A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Pathogen vaccines and methods for using the same
US7393493B2 (en) * 2003-02-27 2008-07-01 A Enterprises, Inc. Crosslinkable polymeric materials and their applications
WO2005030133A2 (en) * 2003-09-22 2005-04-07 Yale University Treatment with agonists of toll-like receptors
US20050118199A1 (en) * 2003-10-07 2005-06-02 Esser Mark T. Process for covalently conjugating polysaccharides to microspheres or biomolecules
US20070275007A1 (en) * 2003-11-05 2007-11-29 The Government Of The United States Of America, Represented By The Secretary Of Health And Human S Carbohydrate Antigen-Nanoparticle Conjugates and Uses Thereof as Antimetastatic Agents in Treating Cancer
US9040090B2 (en) * 2003-12-19 2015-05-26 The University Of North Carolina At Chapel Hill Isolated and fixed micro and nano structures and methods thereof
KR101281775B1 (ko) 2003-12-19 2013-07-15 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 소프트 또는 임프린트 리소그래피를 이용하여 분리된마이크로- 및 나노- 구조를 제작하는 방법
WO2005072778A2 (en) * 2004-01-29 2005-08-11 Biosynexus, Inc. Use of amino-oxy functional groups in the preparation of vaccines conjugates
JP2008532929A (ja) * 2005-02-01 2008-08-21 メディバス エルエルシー ワクチン送達組成物および使用法
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2006282042B2 (en) 2005-06-17 2011-12-22 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials
EP1951202A4 (en) 2005-11-07 2013-03-06 Univ North Carolina ISOLATED AND SOLID MICRO AND NANO STRUCTURES AND METHOD THEREFOR
US8944804B2 (en) * 2006-01-04 2015-02-03 Liquidia Technologies, Inc. Nanostructured surfaces for biomedical/biomaterial applications and processes thereof
US20090220789A1 (en) 2006-01-27 2009-09-03 The University Of North Carolina At Chapel Hill Taggants and methods and systems for fabricating same
KR101711903B1 (ko) * 2006-03-17 2017-03-03 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 복합 다가 면역원성 콘쥬게이트의 제조 방법
WO2008011051A1 (en) * 2006-07-17 2008-01-24 Liquidia Technologies, Inc. Nanoparticle fabrication methods, systems, and materials
US20100055459A1 (en) * 2006-08-30 2010-03-04 Liquidia Technologies, Inc. Nanoparticles Having Functional Additives for Self and Directed Assembly and Methods of Fabricating Same
WO2008033966A2 (en) * 2006-09-12 2008-03-20 Alphavax, Inc. Alphavirus replicon particles matched to protein antigens as immunological adjuvants
WO2008045486A2 (en) 2006-10-09 2008-04-17 The University Of North Carolina At Chapel Hill Nanoparticle compositions for controlled delivery of nucleic acids
US9114238B2 (en) * 2007-04-16 2015-08-25 Corium International, Inc. Solvent-cast microprotrusion arrays containing active ingredient

Similar Documents

Publication Publication Date Title
JP2011525477A5 (enExample)
Kyriakides et al. Biocompatibility of nanomaterials and their immunological properties
Vinay et al. Recent advances in application of nanoparticles in fish vaccine delivery
Gupta et al. Possible role of nanocarriers in drug delivery against cervical cancer
Griffiths et al. Nanobead-based interventions for the treatment and prevention of tuberculosis
Dong et al. Clay nanoparticles as pharmaceutical carriers in drug delivery systems
Meyer et al. Biomimetic particles as therapeutics
UY37326A (es) Dispersiones sólidas extruidas por fusión que contienen un agente inductor de apoptosis
JP2013530158A5 (enExample)
AR093449A1 (es) Polvo farmaceutico compuesto de nucleo-recubrimiento y procedimientos para producirlo
JP2011178784A5 (enExample)
JP2011037876A5 (enExample)
JP2014530219A5 (enExample)
Ferrari et al. Halloysite nanotubes-polymeric nanocomposites: characteristics, modifications and controlled drug delivery approaches
Jain et al. Montmorillonite-PLGA nanocomposites as an oral extended drug delivery vehicle for venlafaxine hydrochloride
JP2014533698A5 (enExample)
JP2008505857A5 (enExample)
JP2013542945A5 (enExample)
JP2014526519A5 (enExample)
Li et al. Nanomaterials in the application of tumor vaccines: advantages and disadvantages
Beletskii et al. Engineered PRINT® nanoparticles for controlled delivery of antigens and immunostimulants
Rofeal et al. Dual therapeutic targeting of lung infection and carcinoma using lactoferrin-based green nanomedicine
Hani et al. Current perspectives on novel drug delivery systems and approaches for management of cervical cancer: a comprehensive review
Yin et al. Biodegradable Imiquimod-Loaded Mesoporous Organosilica as a Nanocarrier and Adjuvant for Enhanced and Prolonged Immunity against Foot-and-Mouth Disease Virus in Mice
Kiriyama et al. Availability of polymeric nanoparticles for specific enhanced and targeted drug delivery